
ACET Stock Forecast & Price Target
ACET Analyst Ratings
Bulls say
Adicet Bio Inc's promising pipeline, particularly the preclinical candidate ADI-270, shows potential advantages in safety and efficacy over traditional αβ CAR-T therapies, suggesting a robust risk-benefit profile for patients with renal cell carcinoma and potentially other indications. The FDA's Fast Track Designation for ADI-001 underscores the therapeutic promise of the company’s allogeneic gamma delta T cell therapies, particularly for autoimmune diseases like systemic sclerosis. Additionally, Adicet's strong cash position of $176.3 million provides the necessary financial stability to continue advancing its clinical programs and enhance shareholder value.
Bears say
Adicet Bio Inc faces significant challenges due to a lack of differentiating clinical data for its drug candidates and the potential approval of competitive therapies, which could hinder future sales potential. Additionally, the company reported a fourth quarter earnings per share (EPS) loss of ($0.32), indicating financial strain, despite ending the quarter with $176.3 million in cash and cash equivalents. The overall high failure rate of drugs in clinical development adds further regulatory and competitive risks to the company's prospects.
This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares